Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo In the Treatment of Acute Exacerbation of Chronic Bronchitis

Trial Profile

Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo In the Treatment of Acute Exacerbation of Chronic Bronchitis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Faropenem medoxomil (Primary)
  • Indications Acute exacerbations of chronic bronchitis; Bacterial infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Cardiovascular Systems
  • Most Recent Events

    • 13 May 2008 The expected completion date for this trial is now 1 Jun 2008, according to ClinicalTrials.gov.
    • 23 Apr 2008 Status changed from recruiting to in progress, as reported by Replidyne.
    • 23 Apr 2008 Enrolment has been discontined by Replidyne to conserve cash assets, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top